FDA Approves Precigen’s Papzimeos for Recurrent Respiratory Papillomatosis”
The U.S. Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba), developed by Precigen,...
Precigen
Precigen’s RRP Therapy PRGN-2012 Gets FDA Review
US-based cell and gene therapy (CGT) specialist Precigen, Inc. (NASDAQ: PGEN) announced that the US...